Review: continuing antidepressants for 12 months following acute treatment may reduce the risk of relapse in depression


QUESTION: In people with depressive disorders, how long should antidepressant treatment be continued to prevent relapse?

Design
Systematic review with meta-analysis.

Data sources
The authors searched the Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials Register (CCDANCTR). This incorporates searches of Medline (1966-April 2000); Embase (1980-April 2000); CINAHL (1982-April 2000); PsycLit (1974-April 2000); PsycInfo (1977-December 1999), and LILACS (1982-December 1999). The reviewers screened the reference lists of all selected studies, other relevant papers and major textbooks, and contacted the authors of identified papers, experts in the field, and manufacturers of antidepressants for additional studies.

Study selection
Published and unpublished randomised trials were eligible if they compared continuing with discontinuing antidepressant treatment in people with depressive disorders who responded to acute treatment. The authors included 31 trials with 4410 participants. Most trials were of 12 months duration.

Data extraction
Two reviewers extracted data about participant, intervention, and outcome characteristics. Data were checked by a third reviewer.

Main results
The average rate of relapse was 41% in people receiving placebo compared with 18% for those continuing antidepressant treatment. Continuing treatment reduced the likelihood of relapse by 70% (95% CI 62% to 78%, p < 0.0001). The reduced risk of relapse appeared largely independent of the initial risk of relapse, duration of previous treatment, and the duration of randomly allocated therapy. A greater number of participants allocated antidepressants withdrew from the trials compared to placebo (18% v 15% respectively, odds ratio 1.30, 95% CI 1.07 to 1.59). Evidence about the effects of continuing antidepressant treatment for more than one year was limited.

Conclusions
Continuing antidepressants for 12 months after acute treatment may benefit many people with recurrent depressive disorder. Further trials are needed to establish the optimum length of therapy, especially for those at low risk of relapse.

COMMENTARY
Concerns about the premature discontinuation of antidepressant treatment in primary care were first expressed 30 years ago. In the absence of long term data from randomised trials, it has been assumed that early cessation of therapy contributes to the preventable morbidity associated with depression. This landmark review by Geddes et al addresses one of the most important clinical dilemmas in the management of depression: how long should antidepressant treatment continue in order to minimise the risk of subsequent relapse?

We do not have a definitive answer to this question, primarily due to the limited data available, most of which come from studies conducted mainly in secondary care settings with patients at high risk of relapse. Despite the limitations inherent in meta-analysis (differences between studies in patients recruited, antidepressants used, length of antidepressant treatment before randomisation, and whether results are reported on an intention to treat basis), this review suggests that an additional year of antidepressant treatment is likely to reduce the risk of relapse by about half in people at high risk, irrespective of which class of antidepressant is used or the length of prior treatment.

For people at lower risk of relapse, the benefit of continuing treatment is less clear. In terms of secondary prevention, this is a key patient group. It is here that the best opportunities lie to prevent development of recurrent depression, where the burden of illness becomes particularly high. These patients tend to be managed in primary care settings. Although available data are fewer for this group, Geddes et al suggest that a continuation of therapy may still be beneficial, though there is a need for prospective randomised studies to confirm these tentative findings.

MRPharm S John Donoghue, BSc
School of Pharmacy and Chemistry
Liverpool John Moores University
United Kingdom